Cargando…
Short-acting β(2)-agonist prescription patterns in patients with asthma in Turkey: results from SABINA III
BACKGROUND: Over-reliance on short-acting β(2)-agonists (SABAs) is associated with poor asthma outcomes. However, the extent of SABA use in Turkey is unclear owing to a lack of comprehensive healthcare databases. Here, we describe the demographics, disease characteristics and treatment patterns from...
Autores principales: | Yorgancıoğlu, Arzu, Aksu, Kurtuluş, Naycı, Sibel Atış, Ediger, Dane, Mungan, Dilşad, Gül, Umut, Beekman, Maarten J. H. I. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9161536/ https://www.ncbi.nlm.nih.gov/pubmed/35655251 http://dx.doi.org/10.1186/s12890-022-02008-9 |
Ejemplares similares
-
Short-acting β(2)-agonist prescription patterns for asthma management in the SABINA III primary care cohort
por: Price, David, et al.
Publicado: (2022) -
Over-prescription of short-acting β(2)-agonists remains a serious health concern in Kenya: results from the SABINA III study
por: Chakaya, Jeremiah, et al.
Publicado: (2023) -
Over-prescription of short-acting β(2)-agonists for asthma in South Africa: Results from the SABINA III study
por: Smith, C, et al.
Publicado: (2022) -
Short-acting β(2)-agonist prescriptions are associated with poor clinical outcomes of asthma: the multi-country, cross-sectional SABINA III study
por: Bateman, Eric D., et al.
Publicado: (2022) -
Short-acting beta-2 agonist prescription patterns and clinical
outcomes in Chinese patients with asthma: an observational study in mainland
China for the SABINA programme
por: Bao, Wuping, et al.
Publicado: (2022)